ES3061217T3 - Crystal forms of crisaborole in free form and preparation method and use thereof - Google Patents

Crystal forms of crisaborole in free form and preparation method and use thereof

Info

Publication number
ES3061217T3
ES3061217T3 ES17795532T ES17795532T ES3061217T3 ES 3061217 T3 ES3061217 T3 ES 3061217T3 ES 17795532 T ES17795532 T ES 17795532T ES 17795532 T ES17795532 T ES 17795532T ES 3061217 T3 ES3061217 T3 ES 3061217T3
Authority
ES
Spain
Prior art keywords
preparation
free form
crisaborole
crystal forms
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17795532T
Other languages
English (en)
Spanish (es)
Inventor
Minhua Chen
Yanfeng Zhang
Fei Lu
Nan Xia
Xiaoyu Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anacor Pharmaceuticals LLC
Original Assignee
Anacor Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60266671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3061217(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anacor Pharmaceuticals LLC filed Critical Anacor Pharmaceuticals LLC
Application granted granted Critical
Publication of ES3061217T3 publication Critical patent/ES3061217T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES17795532T 2016-05-09 2017-05-09 Crystal forms of crisaborole in free form and preparation method and use thereof Active ES3061217T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610301832 2016-05-09
PCT/CN2017/083631 WO2017193914A1 (zh) 2016-05-09 2017-05-09 克立硼罗游离形式的晶型及其制备方法和用途

Publications (1)

Publication Number Publication Date
ES3061217T3 true ES3061217T3 (en) 2026-03-31

Family

ID=60266671

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17795532T Active ES3061217T3 (en) 2016-05-09 2017-05-09 Crystal forms of crisaborole in free form and preparation method and use thereof

Country Status (14)

Country Link
US (1) US11773113B2 (https=)
EP (1) EP3456722B1 (https=)
JP (3) JP2019520321A (https=)
KR (1) KR102221472B1 (https=)
CN (2) CN119751489A (https=)
AU (1) AU2017262235C1 (https=)
BR (1) BR112018073017B1 (https=)
CA (1) CA3023851C (https=)
ES (1) ES3061217T3 (https=)
IL (1) IL262878A (https=)
MX (1) MX380022B (https=)
SG (1) SG11201809984PA (https=)
WO (1) WO2017193914A1 (https=)
ZA (1) ZA201807892B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10329311B1 (en) * 2017-12-21 2019-06-25 Olon S.P.A. Process for the preparation of crisaborole
PL3737685T3 (pl) * 2018-01-09 2023-10-02 Halcyon Labs Private Limited Sposób wytwarzania kryzaborolu i jego związków pośrednich
US10597410B2 (en) 2018-02-02 2020-03-24 Dipharma Francis S.R.L. Intermediates and process for the preparation of a crystalline form of a topical anti-inflammatory agent
CN110780005B (zh) * 2019-11-14 2022-07-29 江苏海岸药业有限公司 一种克立硼罗原料及其合成中间体的分析方法
CN111983123A (zh) * 2020-08-14 2020-11-24 江苏海岸药业有限公司 用于治疗皮肤疾病的克立硼罗制剂的体外评价方法
CN112375093A (zh) * 2020-11-13 2021-02-19 江苏知原药业股份有限公司 一种克立硼罗晶型化合物及其制备方法
CN113087733A (zh) * 2021-04-06 2021-07-09 南京科默生物医药有限公司 克立硼罗的晶型a、晶型b、晶型c、晶型d、晶型e及其制备方法
WO2024047571A1 (en) * 2022-09-01 2024-03-07 Savoi Guilherme Crisaborole cocrystal derivatives
CN115417890A (zh) * 2022-09-24 2022-12-02 中山万远新药研发有限公司 克立硼罗的新晶型及其制备方法与用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191496B (https=) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
NZ578297A (en) 2005-02-16 2010-11-26 Anacor Pharmaceuticals Inc Boron-containing small molecules
EP1976536A4 (en) 2005-12-30 2011-03-02 Anacor Pharmaceuticals Inc SMALL MOLECULES CONTAINING BORON
CN101505603A (zh) * 2005-12-30 2009-08-12 安纳考尔医药公司 含硼的小分子
ME02188B (me) 2006-02-16 2016-02-20 Anacor Pharmaceuticals Inc Mali molekuli koji sadrže boron kao antiinflamatorni agensi
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
RU2008152367A (ru) * 2006-06-12 2010-07-20 Анакор Фармасьютикалз, Инк. (Us) Соединения для лечения периодонтального заболевания
CN102014927A (zh) * 2008-03-06 2011-04-13 安纳考尔医药公司 作为抗炎药的含硼的小分子
EP3383363B1 (en) * 2015-11-30 2021-01-06 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions
WO2017203514A1 (en) * 2016-05-26 2017-11-30 Perrigo Api Ltd Polymorphs of crisaborole and production processes therefor

Also Published As

Publication number Publication date
RU2018142490A3 (https=) 2020-06-10
JP2019520321A (ja) 2019-07-18
RU2018142490A (ru) 2020-06-10
WO2017193914A1 (zh) 2017-11-16
NZ786020A (en) 2025-06-27
AU2017262235C1 (en) 2020-08-20
JP2021167327A (ja) 2021-10-21
EP3456722A4 (en) 2019-12-18
US20230234974A1 (en) 2023-07-27
NZ748385A (en) 2022-03-25
BR112018073017A2 (pt) 2019-02-19
JP2023116645A (ja) 2023-08-22
MX380022B (es) 2025-03-11
KR102221472B1 (ko) 2021-03-02
ZA201807892B (en) 2021-06-30
EP3456722C0 (en) 2025-12-10
CN119751489A (zh) 2025-04-04
SG11201809984PA (en) 2018-12-28
CA3023851A1 (en) 2017-11-16
EP3456722A1 (en) 2019-03-20
BR112018073017B1 (pt) 2022-06-14
US11773113B2 (en) 2023-10-03
CN108884111A (zh) 2018-11-23
CA3023851C (en) 2021-01-26
AU2017262235B2 (en) 2019-09-19
IL262878A (en) 2018-12-31
MX2018013742A (es) 2019-08-01
KR20190005195A (ko) 2019-01-15
AU2017262235A1 (en) 2018-12-06
EP3456722B1 (en) 2025-12-10

Similar Documents

Publication Publication Date Title
ES3061217T3 (en) Crystal forms of crisaborole in free form and preparation method and use thereof
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CL2020000281A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39 y métodos de uso de anticuerpos anti-cd39
CL2018002081A1 (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
ECSP18044917A (es) Compuestos inhibidores de la quinasa de unión a tank
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
MX374012B (es) Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol.
MX2024006565A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
CU20190006A7 (es) Composiciones para inhibir masp-3
CL2016002772A1 (es) Composiciones de insulina de rápida acción
ES3052034T3 (en) Humanized or chimeric cd3 antibodies
CR20180563A (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que lo contienen
MX2019003945A (es) Formas cristalinas y salinas de compuestos agonistas de ppar.
CO2018005753A2 (es) Composición hemostática
BR112021011124A2 (pt) Anelossomos e métodos de uso
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
HUE059216T2 (hu) Készítmény és eljárás annak elõállítására
CO2019011980A2 (es) Formas cristalinas de (s)-afoxolaner
PY18111999A (es) Hidroxiisoxazolinas y derivados de estos
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
MX373845B (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio.
BR112017002090A2 (pt) formulação de fator viii
BR112017024126A2 (pt) composições farmacêuticas e uso das mesmas
MX2017004909A (es) Composiciones de triptamina y metodos de uso.
EP3858327A4 (en) External preparation composition